CRF21 Activators
CRF21 activators are a category of chemical compounds known for their specific interaction with cellular components, particularly targeting the regulatory pathways associated with CRF21, a protein involved in hormonal regulation. These activators are engineered to bind to and modulate the activity of CRF21, influencing the regulation of hormone production and signaling. The relationship between CRF21 activators and their target sites is characterized by complex biochemical reactions that can lead to modifications in protein functionality, potentially impacting the balance and behavior of hormone networks. Unveiling the action mechanism of CRF21 activators encompasses biochemical assays, analysis of binding affinities, and the investigation of the kinetic properties of the activator-receptor interaction, alongside observing the subsequent cellular responses.
The research and refinement of CRF21 activators require an in-depth exploration of structure-activity relationships, as the efficacy of these compounds is intrinsically linked to their molecular architecture. Advanced techniques such as computational modeling, crystallography, or nuclear magnetic resonance (NMR) spectroscopy are often utilized to ascertain the spatial configuration of atoms within the activator molecules, which is crucial for predicting and improving their activity profile. The selectivity of CRF21 activators is paramount since non-specific interactions within the biological system could lead to a cascade of undesired effects. Therefore, the synthesis and iterative optimization of these compounds aim to enhance their precision for CRF21. Investigations into CRF21 activators are deeply entrenched in the fields of biochemistry, focusing on the elemental tenets that underlie molecular interactions and the intricacies of cellular signaling pathways.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin directly stimulates adenylate cyclase, resulting in increased production of cyclic AMP (cAMP). Elevated cAMP levels lead to the activation of protein kinase A (PKA), which in turn can phosphorylate CRF21, thereby enhancing its activity as part of downstream cAMP-dependent signaling pathways. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $27.00 $37.00 | 5 | |
Isoproterenol acts as an agonist for beta-adrenergic receptors, leading to G-protein activation and subsequent increase in cAMP levels. The rise in cAMP activates PKA, which may then phosphorylate and thus enhance the activity of CRF21 within cardiomyocytes or other relevant cell types where CRF21 is expressed. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
PMA activates protein kinase C (PKC), which can phosphorylate various substrates including CRF21. PKC-mediated phosphorylation has been implicated in the regulation of numerous proteins, and if CRF21 is a substrate, this would result in its enhanced activity. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $76.00 $265.00 | 80 | |
Ionomycin is a calcium ionophore that increases intracellular calcium levels, leading to the activation of calcium-dependent signaling pathways. This can indirectly enhance the activity of CRF21 by activating calmodulin-dependent kinase (CaMK), which may phosphorylate CRF21 if it is a target. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $159.00 $315.00 $598.00 | 34 | |
IBMX is a non-selective inhibitor of phosphodiesterases, which prevents the breakdown of cAMP and cGMP in the cell. The resultant increase in cAMP/cGMP levels can lead to activation of PKA or PKG respectively, which can then enhance the activity of CRF21 by phosphorylating it if CRF21 is part of these signaling cascades. | ||||||
L-Arginine | 74-79-3 | sc-391657B sc-391657 sc-391657A sc-391657C sc-391657D | 5 g 25 g 100 g 500 g 1 kg | $20.00 $30.00 $60.00 $215.00 $345.00 | 2 | |
L-Arginine is a substrate for nitric oxide synthase, leading to the production of nitric oxide (NO). NO activates guanylate cyclase, which increases cGMP levels, leading to PKG activation. PKG can then phosphorylate CRF21, resulting in enhanced CRF21 activity if it is a target within these signaling pathways. | ||||||
(−)-Epinephrine | 51-43-4 | sc-205674 sc-205674A sc-205674B sc-205674C sc-205674D | 1 g 5 g 10 g 100 g 1 kg | $40.00 $102.00 $197.00 $1739.00 $16325.00 | ||
Epinephrine binds to and activates beta-adrenergic receptors, which increases cAMP levels through G-protein signaling. The subsequent PKA activation could lead to the phosphorylation and enhancement of CRF21 activity in cells expressing relevant adrenergic receptors. | ||||||
Nicotinic Acid | 59-67-6 | sc-205768 sc-205768A | 250 g 500 g | $61.00 $122.00 | 1 | |
Nicotinic acid acts as a GPR109A receptor agonist, which can lead to inhibition of cyclic AMP breakdown by adenylyl cyclase inhibition. The stabilized cAMP levels can activate PKA, potentially enhancing CRF21 activity through PKA-mediated phosphorylation if CRF21 is implicated in the pathway. | ||||||
Angiotensin II, Human | 4474-91-3 | sc-363643 sc-363643A sc-363643B sc-363643C | 1 mg 5 mg 25 mg 100 mg | $50.00 $75.00 $260.00 $505.00 | 3 | |
Angiotensin II interacts with its G-protein-coupled receptors to activate phospholipase C (PLC), leading to the production of inositol trisphosphate (IP3) and diacylglycerol (DAG), and the release of calcium from intracellular stores. This cascade can enhance CRF21 activity via calcium-dependent or PKC-mediated processes if CRF21 is involved. | ||||||
Vardenafil | 224785-90-4 | sc-362054 sc-362054A sc-362054B | 100 mg 1 g 50 g | $516.00 $720.00 $16326.00 | 7 | |
Vardenafil is a phosphodiesterase-5 inhibitor that prevents the breakdown of cGMP, leading to its accumulation. The resulting activation of PKG could enhance the activity of CRF21 if CRF21 is a target within the cGMP-dependent signaling pathways. | ||||||